Covance CVD
-
New Morningstar Analyst Report - WuXi PharmaTech (Cayman), Inc.
… year.The cancellation of WuXi and Covance 's joint venture for toxicology services deprives WuXi of Covance 's reputation and expertise in the ..... termination of its joint venture with Covance CVD deprives WuXi of significant expertise …
-
Covance's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Covance ( CVD ) Q1 2012 Earnings Call May 03, 2012 10:00 am ET Executives Paul Surdez - William E. Klitgaard - Chief Financial Officer …
-
Late-Stage Outperformance Helps Buoy Weak Early Development Demand in Covance's 1Q
In Covance 's CVD first-quarter results, stronger-than-expected Late-Stage Development ..... 3% from 13.9% in first quarter 2011. On a consolidated basis, Covance 's operating margin declined to 8.7% from 9.5% a year ago, though …
-
Covance ( CVD ): Q1 EPS of $0.06 in-line. Revenue of $530M (+5.7% Y/Y) misses by $1M. (PR)
Covance ( CVD ): Q1 EPS of $0.06 in-line. Revenue of $530M (+5.7% Y/Y) misses by $1M . ( PR ) Post your comment!
-
UPDATE 1- Covance to shut Arizona facility, names new CFO
May 2 (Reuters) - Clinical research services provider Covance Inc said it would shut an Arizona facility as part of a plan to reduce costs, and named a new chief financial officer.
-
New Morningstar Analyst Report - Covance , Inc.
… damaging effect on earnings. Covance derives the vast majority ..... This is especially true for Covance 's early-stage testing ..... revenue opportunities. Covance 's global scale and development ..... next five years. We think Covance is uniquely positioned to …
-
New Morningstar Analyst Report - Charles River Laboratories International Inc.
… drug development spending, which has led to capacity underutilization and pricing pressure. It also competes with Covance CVD , a larger and more established player. We think Charles River's position as the outsourcing market leader for discovery …
-
New Morningstar Analyst Report - ICON PLC
… s consolidated earnings.ICON competes with several larger and more established rivals in the CRO industry, such as Covance and Pharmaceutical Product Development, which boast greater capital resources and staffing capabilities.We expect the …
-
Covance Reports In-Line Fourth Quarter, but IT Investments Expected to Weigh Heavily on 2012 EPS
Although Covance CVD reported fourth-quarter results that ..... completed during the last year, allowed Covance to turn in adjusted diluted earnings per ..... quarter 2010. On the commercial front, Covance recorded record new bookings of $759 …
-
CROs Will Return to Relevance in 2012
… saw widespread top-line growth. Covance CVD and Pharmaceutical Product Development ..... established strategic alliances, like Covance . CROs Still on Sale Overall market ..... top picks in the space. Shares of Covance --one of the highest-quality …